RMOMX
Price
$27.14
Change
+$0.03 (+0.11%)
Updated
Jun 22 closing price
Net Assets
71.02M
VMGMX
Price
$132.08
Change
+$0.31 (+0.24%)
Updated
Jun 22 closing price
Net Assets
33.76B
Interact to see
Advertisement

RMOMX vs VMGMX

RMOMX vs VMGMX Comparison Chart in %
View a ticker or compare two or three
VS
RMOMX vs. VMGMX commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RMOMX is a Hold and VMGMX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VMGMX has more cash in the bank: 33.8B vs. RMOMX (71M). VMGMX pays higher dividends than RMOMX: VMGMX (0.62) vs RMOMX (0.00). RMOMX was incepted earlier than VMGMX: RMOMX (6 years) vs VMGMX (15 years). RMOMX (2.46) is less costly to investors than VMGMX (0.07). RMOMX is a more actively managed with annual turnover of: 88.00 vs. VMGMX (17.00). RMOMX (3000) and VMGMX (3000) have matching initial minimum investment requirements. RMOMX annual gain was more profitable for investors over the last year : 16.95 vs. VMGMX (12.44). VMGMX return over 5 years is better than : 31.82 vs. RMOMX (-18.86).
RMOMXVMGMXRMOMX / VMGMX
Total Expense Ratio1.050.071,500%
Annual Report Gross Expense Ratio2.460.073,514%
Fund Existence6 years15 years-
Gain YTD11.4269.694118%
Front LoadN/AN/A-
Min. Initial Investment30003000100%
Min. Initial Investment IRAN/AN/A-
Net Assets71M33.8B0%
Annual Yield % from dividends0.000.62-
Returns for 1 year16.9512.44136%
Returns for 3 years55.8055.17101%
Returns for 5 years-18.8631.82-59%
Returns for 10 yearsN/A212.40-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TEMUX22.47N/A
N/A
Morgan Stanley Pathway Em Mkts Eq
MRICX26.84N/A
N/A
MFS Research International C
ICSSX16.85N/A
N/A
VY® Columbia Small Cp Val & InflectionS
ALVDX11.11N/A
N/A
American Century Focused Lg Cap Val R6
BRUMX18.25N/A
N/A
MFS Blended Research Value Equity R4